A General Model of the Effects of Sleep Medications on the Risk and Cost of Motor Vehicle Accidents and its Application to France
Background: Although various prescription drugs may be equally effective in promoting sleep, some may lead to substantial impairment in psychomotor functioning and an increased risk of motor vehicle accidents.
Objective: To develop a general model to evaluate the potential effects of sleep medications on motor vehicle accidents and costs, and apply the model to the French setting.
Methods: Impairment in driving performance, as evaluated by randomised controlled open-road studies using the standard deviation of a vehicle’s lateral position (SDLP), a measure of weaving, was expressed in terms of equivalent blood alcohol (ethanol) concentration (BAC). Epidemiological data were then used to relate BAC to the excess risk of motor vehicle accidents. Although a non-impairing medication would not increase risk, a medication that produces mild impairment in driving performance (a change of 2.5cm in SDLP, equivalent to 0.05% BAC) would increase motor vehicle accident risk by 25%. One that leads to moderate impairment (an SDLP change of 4.5cm, equivalent to 0.08% BAC) would roughly double this risk, and a severely impairing medication (an SDLP change of 7cm, equivalent to 0.12% BAC) would result in up to a 5-fold increase in motor vehicle accident risk. For application to the French setting, a hypothetical cohort of 100 000 adult drivers with insomnia was assumed to be treated for 14 days either with zaleplon 10mg, a new sleep medication that has been shown not to significantly impair driving performance, or zopiclone 7.5mg, which has been shown to cause moderate impairment.
Results: Compared with zaleplon, use of zopiclone over 14 days in France would be expected to result in 503 excess accidents per 100 000 drivers at an additional cost of 158 French francs (31 US dollars) per person (1996 values).
Conclusions:Our model illustrates the extent to which non-impairing sleep medications could reduce the burden posed by motor vehicle accidents. Our model is designed to be general, and thus can serve as the basis for similar investigations.
KeywordsZolpidem Motor Vehicle Accident Zopiclone Flunitrazepam Zaleplon
This study was funded in part by the Wyeth-Ayerst Global Health Outcomes Assessment Group, Radnor, PA. We would like to thank Charlotte McMillan, PhD, George Sillup, PhD, and George France for their helpful comments and suggestions on the model. We also would like to thank Luke Boulanger, MA, and Shawn O’Donoghue for their assistance in conducting the study.
- 4.National Sleep Foundation. Sleep in America: 1995. Washington, DC: National Sleep Foundation, 1995Google Scholar
- 11.Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16 (5): 263–87Google Scholar
- 15.Flemming JA, McClure DJ, Mayes C, et al. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 29–37Google Scholar
- 18.Ponciano E, Frietas F, Camara J, et al. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam, and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990; 52 Suppl.: 69–77Google Scholar
- 22.Volkerts ER, O’Hanlon JF. Hypnotics’ residual effects on driving performance. In: O’Hanlon JF, de Gier JJ, editors. Drugs and driving. Philadelphia (PA): Taylor & Francis, 1985: 123–35Google Scholar
- 23.O’Hanlon JF, Brookhuis KA, Louwerens JW, et al. Performance testing as part of drug registration. In: O’Hanlon JF, de Gier JJ, editors. Drugs and driving. Philadelphia (PA): Taylor & Francis, 1985: 311–30Google Scholar
- 30.Lacronique JF. Benzodiazepines: le point de vue de l’economiste. Psychologie Medicale 1989; 21A (hors serie): 79–88Google Scholar
- 31.Lagier G et al. Livre blanc: sécurité routière, drogues licites ou illicites et médicaments. Rapport au Premier Ministre. Paris: La Documentation Française, 1996Google Scholar
- 32.OECD health data 1999 [CD-ROM]. Washington, DC: Brookings Press, 2000Google Scholar
- 33.Louwerens JW, Gloerich ABM, de Vries G, et al. The relationship between drivers’ blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Nordzij PC, Roszbach R, editors. Alcohol, drugs and traffic safety — T86. Amsterdam: Excerpta Medica, 1986: 183–6Google Scholar
- 34.Borkenstein RF, Crowther RF, Shumate RP, et al. The role of the drinking driver in traffic accidents. Blutalkohol 1974; 11 Suppl. 1: 1–131Google Scholar
- 35.Fontaine H, Hubert JP, Lejeune M. Exposition au risque et risque d’accident des conducteurs de véhicules légers. Arcueil: INRETS (Institut National de Recherche sur les Transports et leur Sécurité), 1997 Oct. DERA Report No.: 9708Google Scholar
- 36.Observatoire National Interministériel de Sécurité Routière. Bilan annuel. Statistiques et Commentaires, année 1996. Paris: La Documentation Française, 1997Google Scholar